Stuart Louis Cramer, DO
Fax: (803) 434-3094
About us
Stuart Cramer, DO, joined Prisma Health in 2017 as the medical director of the Children's Center for Cancer and Blood Disorders. Originally from Florida, he received his medical degree at Nova Southeastern University College of Osteopathic Medicine and completed his pediatric hematology/oncology fellowship at the University of Alabama Children’s Hospital in Birmingham, where he was the director of developmental therapeutics.
As part of his honors thesis while in college, Dr. Cramer pursued three years of scientific research, which provoked his appreciation of merging basic science with clinical medicine. His fellowship training solidified his interest in cancer cell biology, and afforded him the opportunity to expand his research experience focusing on novel therapeutics. With his research background, he has developed a broad knowledge of drug resistance within pediatric solid tumors and the role of novel therapeutics in the treatment of pediatric solid tumors. Cramer’s current focus is on developing a therapeutics program based in Columbia, enabling pediatric patients access to novel therapies developed both nationally and locally.
| Tags | breast cancer immunotherapy, total body irradiation, sarcoma, rhabdomyosarcoma, retinoblastoma, oral lesions, odontogenic tumors, neuroblastoma, nephroblastoma, metastatic brain cancer, malignant rhabdoid tumor, juvenile myelomonocytic leukemia, glioma, germinoma, germ cell tumor, ewings sarcoma, egfr mutation, cns lymphoma, chronic myelocytic leukemia, cervical teratoma, carcinoma of unknown primary, beckwith wiedemann syndrome, adverse effects to anticoagulants, anemia, anemia of chronic disease, antithrombin deficiency, aplastic anemia, b12 deficiency anemia, blood cancer, blood disorders, bone marrow disorders, cooley anemia, cryoglobulinemia, bleeding disorder, familial aplastic anemia, hemolytic anemia, hemophilia, heparin induced thrombocytopenia, hypogammaglobulinemia, idiopathic thrombocytopenic purpura, iron deficiency anemia, langerhans cell histiocytosis, leukopenia, lymphopenia, myeloproliferative diseases, neutropenia, paroxysmal nocturnal hemoglobinuria, petechiae, polycythemia, porphyria, pure red cell aplasia, purpura, rh incompatibility, secondary polycythemia, sickle cell disease, splenomegaly, thalassemia, thrombocytopenia, thrombocytosis, thrombophilia, von willebrand disease, pancytopenia, acute myelogenous leukemia (aml), hemolytic uremic syndrome, lymphoma, non hodgkin lymphoma, diamond blackfan anemia, dyskeratosis congenita, factor eight disorder, factor nine deficiency, peutz jeghers syndrome, plasma cell dyscrasia, pleomorphic xanthoastrocytomas, teratogen exposure, pediatric cancer, blood clotting disorder, factor v leiden, hellp syndrome, hemochromatosis, myelodysplastic syndrome, primary systemic amyloidosis, adjuvant chemotherapy, anaplastic cancer of thyroid, biological targeted therapy, cancer chemotherapy, cancer genomics, chemoradiation, early detection of cancer, epithelioid hemangioendothelioma, cancer immunotherapy, li fraumeni syndrome, acute lymphoblastic leukemia (all), fanconi anemia, hemolytic disease of the fetus, hypercoagulable state, leukemia, pernicious anemia, severe congenital neutropenia, hemoglobinopathies, splenic sequestration |